| #10 – Pneumovax |
| Pneumococcal infection |
| 2013 – $653 million |
| 2012 – $580 million |
| Marketed by Merck and Sanofi Pasteur MSD |
| #9 – RotaTeq |
| Rotaviral gastroenteritis |
| 2013 – $691 million |
| 2012 – $648 million |
| Marketed by Merck and Sanofi Pasteur MSD |
| #8 – Zostavax |
| Herpes Zoster (Shingles) |
| 2013 – $826 million |
| 2012 – $ N/A |
| Marketed by Merck and Sanofi Pasteur MSD |
| #7 – Hepatitis vaccine franchise |
| Hepatitis A, Hepatitis B |
| 2013 – $984 million |
| 2012 – $986 million |
| Marketed by GSK |
| #6 – Infanrix/Pediarix |
| Diptheria, Tetanus, Pertussis, Hepatitis B, Polio |
| 2013 – $1.349 billion |
| 2012 – $1.83 billion |
| Marketed by GSK |
Top selling vaccines 2013 #5 to #1 >
